Price
$2.14
Decreased by -2.73%
Dollar Volume
251.61 K
ADR%
6.76
Earnings Report Date (estimate)
Nov 10, 22 (-1.53)
Market Cap.
10.90 M
Shares Float
5.03 M
Shares Outstanding
5.09 M
Beta
5.38
Price / Earnings
2.00
BPR
0.40
20D Range
2.11 2.58
50D Range
1.94 7.20
200D Range
1.94 7.20
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 10, 22 -1.50
Decreased by -4.90%
-1.64
Increased by +8.54%
Aug 11, 22 5.58
Increased by +418.86%
-1.33
Increased by +519.55%
May 12, 22 -1.55
Increased by +5.49%
-1.15
Decreased by -34.78%
Mar 24, 22 -1.27
Increased by +33.85%
-1.29
Increased by +1.55%
Nov 12, 21 -1.43
Increased by +31.90%
-1.47
Increased by +2.72%
Aug 12, 21 -1.75
Increased by +16.67%
-1.84
Increased by +4.89%
May 11, 21 -1.64
Decreased by -284.27%
1.69
Decreased by -197.04%
Mar 31, 21 -1.92
Increased by +19.33%
-1.22
Decreased by -57.38%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by -100.00%
-7.64 M
Decreased by -9.25%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by -100.00%
28.01 M
Increased by +453.13%
Increased by +N/A%
Increased by +N/A%
Mar 31, 22 3.11 M
Increased by +28.62%
-7.70 M
Decreased by -6.08%
Decreased by -247.17%
Increased by +17.53%
Dec 31, 21 -2.54 M
Decreased by -207.08%
-6.27 M
Decreased by -88.83 K%
Increased by +246.83%
Increased by +83.15 K%
Sep 30, 21 3.10 M
Increased by +111.62%
-7.00 M
Decreased by -3.03%
Decreased by -226.00%
Increased by +51.31%
Jun 30, 21 3.11 M
Increased by +557.51%
-7.93 M
Decreased by -16.60%
Decreased by -255.05%
Increased by +82.27%
Mar 31, 21 2.42 M
Increased by +N/A%
-7.26 M
Decreased by -350.47%
Decreased by -299.71%
Decreased by N/A%
Dec 31, 20 2.37 M
Decreased by -73.72%
-7.05 K
Increased by +99.91%
Decreased by -0.30%
Increased by +99.67%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.